Tetrahydro-Beta-Carbolines

ABSTRACT

The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT 2B  receptor.

This application is a division of application Ser. No. 08/444,449 filedMay 19, 1995, now U.S. Pat. No. 5,643,916.

FIELD OF THE INVENTION

The present invention relates to the field of organic chemistry. Theinvention provides novel tetrahydro-beta-carboline compounds andintermediates with a high affinity for the 5-HT_(2B) receptor.

BACKGROUND OF THE INVENTION

Blocking serotonin receptors has been shown to result in a number ofbeneficial pharmacological effects, including reduction in diseasestates such as hypertension, depression, anxiety, and the like; see U.S.Pat. No. 5,141,944. Nelson et al., Psychopharmacology and Biochemistryof Neurotransmitter Receptors, eds. H. I. Yamamura et al.,Elsevier/North Holland Inc., p 325, have confirmed that there aremultiple serotonin recognition sites. The general class of serotoninreceptors are referred to as the 5-HT receptors. Specific 5-HT receptorsites include 5-HT_(1A), 5-HT_(1B), 5-HT_(1D), 5-HT_(2A), 5-HT_(2B),5-HT_(2C), 5-HT₃, and 5-HT₄ sites. Each of these receptors mediatescertain physiological effects. See Leonard, B. E., InternationalClinical Psychopharmacology, 7:13-21 (1992).

This invention provides new compounds and a method for using suchcompounds which are active at the 5-HT_(2B) receptor to treat or prevent5-HT_(2B) related conditions. Further, this invention provides a methodfor selectively blocking the 5-HT_(2B) receptor. Additionally, thisinvention provides a method for blocking human 5-HT_(2B) receptors.

This invention provides a group of compounds which are 5HT_(2B) receptorantagonists. Applicants have discovered that such compounds are potentcompetitive inhibitors of serotonin-induced contraction of the colon.Thus, this invention provides compounds which can act to normalizegastrointestinal motility and be useful in the treatment of FunctionalBowel Disorders.

Further, it has been discovered the 5-HT_(2B) receptor is localized inthe rat lung, stomach fundus, uterus, bladder, and colon. Interestingareas of 5-HT_(2B) receptor localization in the human include but arenot limited to the brain and blood vessels. Thus, conditions which canbe treated using a compound which modulates a 5-HT_(2B) receptorincludes, for example, psychosis, depression, anxiety disorders, uterinediseases such as endometriosis, fibrosis, and other abnormal uterinecontractivity, panic attack, migraine, eating disorders, seasonalaffective disorder, consumption disorders, cardiovascular conditions,such as thrombosis, hypertension, angina, vasospasm, and other vascularocclusive diseases, incontinence, bladder dysfunction,respiratory/airway disorders including asthma, and the like.

SUMMARY OF THE INVENTION

This invention provides a group of novel compounds with 5-HT_(2B)receptor activity. Additionally, the present compounds are useful toolsto characterize the effects of the 5-HT_(2B) receptor and to developtherapeutic agents based on 5-HT_(2B) receptor modulation.

The present invention provides compounds of the Formula I ##STR1##wherein Q is selected from the group consisting of hydrogen, R₃₄, and(CHR₂)R₄ ;

R₃₄ is spiro-bicyclic, substituted spiro-bicyclic, bicyclic orsubstituted bicyclic;

R₁ is hydrogen or C₁ -C₃ alkyl;

R₂ is hydrogen or C₁ -C₆ alkyl;

R₃ is hydrogen or C₁ -C₃ alkyl;

R₄ is C₅ -C₈ cycloalkyl, substituted C₅ -C₈ cycloalkyl, C₅ -C₈cycloalkenyl, substituted C₅ -C₈ cycloalkenyl, bicyclic or substitutedbicyclic;

A is selected from the group consisting of ##STR2## wherein R₆ and R₇are, independently, hydrogen, C₁ -C₆ alkyl, C₂ -C₆ alkenyl, halo,halo(C₁ -C₆)alkyl, halo(C₂ -C₆)alkenyl, COR₅, C₁ -C₁₀ alkanoyl, CO₂R_(5'), (C₁ -C₆ alkyl)_(m) amino, NO₂, --SR₅, or OR₅ ;

m is 1 or 2;

R₅ is independently hydrogen or C₁ -C₄ alkyl;

R_(5') is C₁ -C₄ alkyl;

R₈ is independently selected from the group consisting of an R₆ group,substituted C₃ -C₈ cycloalkyl, C₃ -C₈ cycloalkyl, C₃ -C₈ cycloalkyl-(C₁-C₃)alkyl, C₅ -C₈ cycloalkenyl, substituted C₅ -C₈ cycloalkenyl, C₅ -C₈cycloalkenyl-(C₁ -C₃)alkyl, C₇ -C₁₆ arylalkyl; or

R₆ and R₇ together with the carbon atoms of group A form a 5- to8-member carbon ring;

R³⁰ and R³¹ join to form a 3 to 8 member carbon ring; or

R³⁰ and R³¹ are independently selected from the group consisting of C₁-C₆ alkyl and C₂ -C₆ alkenyl; or

a pharmaceutically acceptable salt or solvate thereof.

This invention provides compounds of Formula II ##STR3## A is selectedfrom the group consisting of ##STR4## wherein R₆ and R₇ are,independently, hydrogen, C₁ -C₆ alkyl, C₂ -C₆ alkenyl, halo, halo(C₁-C₆)alkyl, halo(C₂ -C₆)alkenyl, COR₅, C₁ -C₁₀ alkanoyl, CO₂ R_(5'), (C₁-C₆ alkyl)_(m) amino, NO₂, --SR₅, or OR₅ ;

m is 1 or 2;

R₈ is selected from the group consisting of hydrogen, C₁ -C₆ alkyl, C₂-C₆ alkenyl, halo, halo(C₂ -C₆)alkyl, halo(C₁ -C₆)alkenyl, COR₅, C₁ -C₁₀alkanoyl, CO₂ R_(5'), (C₁ -C₆ alkyl)_(m) amino, NO₂, --SR₅, OR₅,substituted C₃ -C₈ cycloalkyl, C₃ -C₈ cycloalkyl, C₃ -C₈ cycloalkyl-(C₁-C₃)alkyl, C₅ -C₈ cycloalkenyl, substituted C₅ -C₈ cycloalkenyl, C₅ -C₈cycloalkenyl-(C₁ -C₃)alkyl, and C₇ -C₁₆ arylalkyl;

R₅ is independently hydrogen or C₁ -C₄ alkyl;

R_(5') is C₁ -C₄ alkyl;

R₆ and R₇ together with the carbon atoms of group A form a 5- to8-member carbon ring;

R₉ and R₁₀ are independently selected from the group consisting ofhydrogen, C₁ -C₆ alkyl, substituted C₃ -C₈ cycloalkyl, C₃ -C₈cycloalkyl, C₃ -C₈ cycloalkyl-(C₁ -C₃)alkyl, C₅ -C₈ cycloalkenyl-(C₁-C₃)alkyl, C₇ -C₁₆ arylalkyl;

R₁₁ is selected from the group consisting of C₁ -C₄ alkyl, OR_(5'),fluoro, bromo, iodo, and chloro;

R³⁰ and R³¹ join to form a 3 to 8 member carbon ring; or

R³⁰ and R³¹ are independently selected from the group consisting of C₁-C₆ alkyl and C₂ -C₆ alkenyl; or

a pharmaceutically acceptable salt or solvate thereof.

DETAILED DESCRIPTION OF THE INVENTION

The term "treating" as used herein includes prophylaxis of the namedphysical and/or mental condition or amelioration or elimination of thedeveloped physical and/or mental condition once it has been established.

The terms "C₁ -C_(n) alkyl" wherein n=2-10, as used herein, represent abranched or linear alkyl group having from one to the specified numberof carbon atoms. Typical C₁ -C₆ alkyl groups include methyl, ethyl,n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl,hexyl and the like.

The terms "C₂ -C_(n) alkenyl" wherein n=3-10, as used herein, representsan olefinically unsaturated branched or linear group having from 2 to 10carbon atoms and at least one double bond. The groups can be branched orstraight chain. Examples of such groups include 1-propenyl,2-propenyl(--CH₂ --CH═CH₂), 1,3-butadienyl(--CH═CHCH═CH₂),1-butenyl(--CH═CHCH₂ CH₃), hexenyl, pentenyl, and the like.

The terms "halide", "halogen", and "halo" include fluorine, chlorine,bromine, and iodine. The preferred halogen is chlorine.

The terms "halo(C₁ -C₆)alkyl" and "halo(C₂ -C₆)alkenyl" refer to alkylor alkenyl substituents having one or more independently selected haloatoms attached at one or more available carbon atoms. These termsinclude chloromethyl, bromoethyl, trifluoroethyl, trifluoromethyl,trifluoroethylenyl, 3-bromopropyl, 3-bromo-1-propenyl, 2-bromopropyl,2-bromo-1-propenyl, 3-chlorobutyl, 3-chloro-2-butenyl,2,3-dichlorobutyl, chloroethylenyl, 5-fluoro-3-pentenyl,3-chloro-2-bromo-5-hexenyl, 3-chloro-2-bromobutyl, trichloromethyl,dichloroethyl, 1,4-dichlorobutyl, 3-bromopentyl, 1,3-dichlorobutyl,1,1-dichloropropyl, and the like. More preferred halo-(C₁ -C₆)alkylgroups are trichloromethyl, trichloroethyl, and trifluoromethyl. Themost preferred halo-(C₁ -C₆)alkyl is trifluoromethyl.

The term "C₁ -C₁₀ alkanoyl" represents a group of the formula C(O)(C₁-C₉) alkyl. Typical C₁ -C₁₀ alkanoyl groups include acetyl, propanoyl,butanoyl, and the like.

The term "(C₁ -C₆ alkyl)_(m) amino" wherein m=1-2; refers to either amono- or a dialkylamino group in which the alkyl portion of the groupmay be straight or branched. Examples of such groups are methylamino,dimethylamino, ethylamino, diethylamino, 2-propylamino, 1-propylamino,di(n-propyl)amino, di(iso-propyl)amino, methyl-n-propylamino,t-butylamino, and the like.

The term "C₃ -C_(n) cycloalkyl" wherein n=4-8, represents cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

The term "substituted (C₅ -C_(n))cycloalkyl" refers to a cycloalkylgroup as described supra wherein the cycloalkyl group may be substitutedwith from one to four substituents independently selected from the groupconsisting of hydrogen, C₁ -C₆ alkyl, NO₂, halo, halo(C₁ -C₆)alkyl,halo(C₂ -C₆)alkenyl, C₂ -C₆ alkenyl, CO₂ R₅, (C₁ -C₆ alkyl)_(m) amino,--SR₅, and OR₅.

The term "C₃ -C₈ cycloalkyl-(C₁ -C₃)alkyl" represents a linear alkylgroup substituted at a terminal carbon with a C₃ -C₈ cycloalkyl group.Typical cycloalkylalkyl groups include cyclohexylethyl,cyclohexylmethyl, 3-cyclopentylpropyl, and the like.

The term "C₅ -C₈ cycloalkenyl" represents an olefinically unsaturatedring having five to eight carbon atoms, eg., cyclohexadienyl,cyclohexenyl, cyclopentenyl, cycloheptenyl, cyclooctenyl,cyclohexadienyl, cycloheptadienyl, cyclooctatrienyl and the like.

The terms `substituted phenyl` and "(C₅ -C₈)cycloalkenyl" refer to aphenyl or cycloalkenyl group as described supra wherein the group may besubstituted with from one to four substituents independently selectedfrom the group consisting of hydrogen, C₁ -C₆ alkyl, NO₂, halo, halo(C₁-C₆)alkyl, halo(C₂ -C₆)alkenyl, C₂ -C₆ alkenyl, COR₅, C₁ -C₁₀ alkanoyl,C₇ -C₁₆ arylalkyl, CO₂ R₅, (C₁ -C₆ alkyl)_(m) amino, --SR₅, and OR₅.

The terms `phenyl-(C₁ -C₃)alkyl` and "C₅ -C₈ cycloalkenyl-(C₁ -C₃)alkyl"represent a linear C₁ -C₃ alkyl group substituted at a terminal carbonwith phenyl or a C₅ -C₈ cycloalkenyl group.

The term "aryl" represents phenyl or naphthyl. The aryl group can beunsubstituted or can have one or two substituents independently selectedfrom the group consisting of C₁ -C₆ alkyl, C₃ -C₈ cycloalkyl,substituted C₃ -C₈ cycloalkyl, C₂ -C₆ alkenyl, C₃ -C₈ cycloalkyl-(C₁-C₃)alkyl, phenyl, C₅ -C₈ cycloalkenyl, substituted C₅ -C₈ cycloalkenyl,C₅ -C₈ cycloalkenyl-(C₁ -C₃)alkyl, COR₅, C₁ -C₁₀ alkanoyl, OR₅, and C₇-C₁₆ arylalkyl. The substituents may be located at any availableposition on the aryl ring.

The term "C₇ -C₂₀ arylalkyl" represents an aryl-(C₁ -C₁₀)alkylsubstituent wherein the alkyl group is linear, such as benzyl,phenethyl, 3-phenylpropyl, or phenyl-t-butyl; or branched. The alkylportion bonds at the point of attachment to the parent molecule.

The term "bicyclic" represents either an unsaturated or saturated stable7- to 12-membered bridged or fused bicyclic carbon ring. The bicyclicring may be attached at any carbon atom which affords a stablestructure. The term includes, but is not limited to, naphthyl,dicyclohexyl, dicyclohexenyl, and the like.

The term "unsaturated bicyclic" represents a stable bicyclic ring of 7to 12 carbon atoms. The unsaturated bicyclic ring may be attached at anycarbon atom which affords a stable structure. The unsaturated bicyclicring may be substituted with from one to four substituents as definedfor "substituted bicyclic" infra.

The general term "substituted bicyclic" refers to a bicyclic ring systemwith 4 substituents attached at any desired positions on the bicyclicring system. The bicyclic substituents may be independently selectedfrom the group consisting of hydrogen, C₁ -C₆ alkyl, NO₂, halo, halo(C₁-C₆)alkyl, halo(C₂ -C₆)alkenyl, C₂ -C₆ alkenyl, COR₅, C₁ -C₁₀ alkanoyl,C₇ -C₁₆ arylalkyl, CO₂ R₅, (C₁ -C₆ alkyl)_(m) amino, --SR₅, and OR₅ ;wherein R₅ is defined supra. It is intended that the substitutedbicyclic substituent may bond to the CHR₂ group through any availablecarbon atom in the bicyclic ring system. The term includes, but is notlimited to compounds such as, 2-methyldicyclohexyl,3-hydroxydicyclohexyl, benzocyclohexyl, benzocyclohexenyl,2-methoxybenzocyclohexyl, 6-chlorobenzocyclohexenyl,8-ethenylbenzocyclohexyl, and the like. The term "spiro-bicyclic" and"substituted spiro-bicyclic" refer to a bicyclic or substituted bicyclic(as defined supra.) directly attached to the carbon of the parent ringat Q. For illustration purposes, a spiro-bicyclic is attached as shown:##STR5##

The term "naphthyl" refers to a naphthalene ring system substituent, ascommonly used in organic chemistry. The naphthyl substituent may bond tothe CHR₂ group through any available carbon atom in the naphthyl ringsystem. The term "substituted naphthyl" refers to a naphthyl ring systemwith 4 sustituents attached at any desired positions on the naphthylring system. The naphthyl substituents may be independently selectedfrom the "substituted bicyclic" group supra.

The term "selective binding of a 5-HT_(2B) receptor" refers to a methodof binding the 5-HT_(2B) receptor to a greater extent than it binds the5-HT_(2A) and/or 5-HT_(2C) receptors.

The term "protic acid" refers to an acid having an acidic hydrogen.Preferred protic acids include hydrochloric acid, formic acid,perchloric acid, sulfuric acid, and phosphoric acid in an aqueousmedium. The most preferred protic acids are hydrochloric acid, sulfuricacid, and formic acid.

The term "organic solvent" includes solvents containing carbon, such ashalogenated hydrocarbons, ether, toluene, xylene, benzene, andtetrahydrofuran.

The term "agitate" includes such techniques as stirring, centrifugation,mixing, and other similar methods.

The term "aprotic solvent" refers to polar solvents of moderately highdielectric constant which do not contain an acidic hydrogen. Examples ofcommon aprotic solvents are dimethyl sulfoxide (DMSO),dimethylformamide, sulfolane, tetrahydrofuran, diethyl ether,methyl-t-butyl ether, or 1,2-dimethoxyethane.

The term "protic solvent" refers to a solvent containing hydrogen thatis attached to oxygen, and hence is appreciably acidic. Common proticsolvents include such solvents as water, methanol, ethanol, 2-propanol,and 1-butanol.

The term "inert atmosphere" refers to reaction conditions in which themixture is covered with a layer of inert gas such as nitrogen or argon.

Abbreviations used herein have their accepted meaning, unless statedotherwise. For example, "Me" and "Et" refer to methyl, ethylrespectively, and "t-Bu" refers to tertiary-butyl. The abbreviation "RT"refers to room temperature or ambient conditions unless indicatedotherwise.

The term "ligand" refers to compounds that are bound by the 5-HT_(2B)and/or 5-HT₂ receptor. Compounds useful as 5-HT_(2B) selective ligandsmay be used to selectively occupy a 5-HT_(2B) receptor site or may actas a selective agonist at a 5-HT_(2B) receptor site.

The term "substantially pure" is intended to mean at least about 90 molepercent, more preferably at least about 95 mole percent, and mostpreferably at least about 98 mole percent of the desired enantiomer orstereoisomer is present compared to other possible configurations.

As used herein the term "functional bowel disorder" refers to afunctional gastrointestinal disorder manifested by (1) abdominal painand/or (2) symptoms of disturbed defecation (urgency, straining, feelingof incomplete evacuation, altered stool form consistency! and alteredbowel frequency/timing) and/or (3) bloating (distention). The term"functional bowel disorder" includes but is not limited to irritablebowel syndrome, hypermotility, ichlasia, hypertonic lower esophogealsphincter, tachygastria, constipation, hypermotility associated withirritable bowel syndrome.

The formula (I), (II) and all compounds claimed herein can form acidaddition salts with a wide variety of inorganic and organic acids.Typical acids which can be used include sulfuric, hydrochloric,hydrobromic, phosphoric, hypophosphoric, hydroiodic, sulfamic, citric,acetic, maleic, malic, succinic, tartaric, cinnamic, benzoic, ascorbic,mandelic, p-toluenesulfonic, benzenesulfonic, methanesulfonic,trifluoroacetic, hippuric and the like. The pharmaceutically acceptableacid addition salts of the Formula (I) and (II) compounds are especiallypreferred.

The compounds of the present invention are useful for modulating orblocking the 5-HT₂ receptor. Certain of the present compounds arepreferred for that use. The following invention embodiments and compoundcharacteristics listed in tabular form may be independently selected orcombined to produce a variety of preferred compounds and embodiments ofthe invention. The following list of embodiments of this invention is inno way intended to limit the scope of this invention in any way.

A) R₁ is hydrogen;

B) R₂ is hydrogen or methyl;

C) R₃ is hydrogen or methyl;

D) R₄ is C₅ -C₈ cycloalkenyl or substituted C₅ -C₈ cycloalkenyl, whereinthe substituents are selected from the group consisting of hydrogen, C₁-C₆ alkyl, NO₂, halo, halo(C₁ -C₆)alkyl, C₂ -C₆ alkenyl, COR₅, (C₁ -C₆alkyl)_(m) amino, --SR₅, and OR₅ ;

E) A is a group of formula III;

F) A is a group of formula IV wherein R₆ and R₇ are C₁ -C₆ alkyl orhalo, and R₈ is hydrogen, C₁ -C₅ alkyl, halo, C₅ -C₈ cycloalkyl, phenylor substituted-phenyl;

G) R₂ is hydrogen;

H) R₃ is hydrogen;

I) R₄ is substituted C₅ -C₈ cycloalkenyl; wherein the substituents areselected from the group consisting of hydrogen, NO₂, halo, (C₁ -C₆alkyl)_(m) amino, and OR₅ ;

J) A is a group of formula IV wherein R₆ is hydrogen, R₇ and R₈ areindependently selected from the group consisting of halo and C₁ -C₄alkyl.

K) Q is (CHR₂)R₄ ;

L) R³⁰ and R³¹ join to form a 3 to 6 member carbon ring;

M) R³⁰ and R³¹ join to form a 3 to 5 member carbon ring;

N) R³⁰ and R³¹ are each methyl;

O) R₄ is naphthyl;

P) R₄ is an optionally substituted bicyclic hydrocarbon ring systemhaving 7 to 12 carbon atoms and 0, 1, 2, or 5 double bonds;

Q) R₄ is a 6 to 10 carbon atom unsaturated bicyclic ring system;

R) Q is bicyclic or substituted bicyclic;

S) R₃₄ is ##STR6## T) R₃₄ is an optionally substituted bicyclic ringsubstituent; U) R₉ and R₁₀ are each hydrogen;

V) R₉ is selected from the group consisting of C₁ -C₆ alkyl, substitutedC₃ -C₈ cycloalkyl, C₃ -C₈ cycloalkyl, C₃ -C₈ cycloalkyl-(C₁ -C₃)alkyl,C₅ -C₈ cycloalkenyl-(C₁ -C₃)alkyl, C₇ -C₁₆ arylalkyl;

W) R₄ is aromatic;

X) R₃₄ is spiro-bicyclic or substituted spiro-bicyclic;

Y) Q is hydrogen.

The more preferred classes have the following features:

A-C, E or F, I, L, N, P, R, and W.

The most preferred class of compounds has the following features:

A, G-J, M, and Q.

The preferred classes of compounds for use as selective 5-HT_(2B)ligands have the following features:

A-D, E or J, M, and O.

The most preferred class of compounds for use as selective 5-HT_(2B)ligands has the following features:

A, G-J, M, and O.

Compounds of Formulas I and II are particularly useful for modulating5HT_(2B) receptors. Certain compounds within the scope of this inventionare preferred for that use. The following invention embodiments andcompound characteristics listed in tabular form may be independentlyselected or combined to produce a variety of preferred compounds andembodiments of the invention. The following list of embodiments of thisinvention is in no way intended to limit the scope of this invention inany way.

A) R₉ and R₁₀ are each hydrogen;

B) R₁₁ is C₁ -C₃ alkyl;

C) R₁₁ is chloro, fluoro, or bromo;

D) R₁₁ is --OCH₃ ;

E) R³⁰ and R³¹ join to form a 3 to 8 member carbon ring;

F) R³⁰ and R³¹ join to form a 3 to 6 member carbon ring;

G) A compound having preferred compound characteristics described supra;

H) A method for binding a 5HT_(2B) receptor using one or more compoundsof Formula I and/or II;

I) A method of using one or more compounds of Formula I and/or II fortreating a functional bowel disorder.

I) A method of using one or more compounds of Formula I and/or II whichare useful for modulation of the 5HT_(2B) receptor for treating afunction bowel disorder.

J) A method for using one or more compounds of Formula I and/or II fortreating Irritable Bowel Syndrome.

K) A pharmaceutical formulation comprising a compound of Formula Iand/or II and one or more pharmaceutically acceptable excipients.

Examples of compounds of Formula I include but are not limited to:

10-methyl-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo 2,3-c!quinoline,8-chloro-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo 2,3-c!quinoline,6-(2,4-dimethoxybenzyl)-10-methyl-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo2,3-c!quinoline,7-fluoro-6-(2,4-dimethoxybenzyl)-10-methyl-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo2,3-c!quinoline,8-methoxy-6-(2,4-dimethoxybenzyl)-10-methyl-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo2,3-c!quinoline,7-nitro-6-(3,4-dimethoxybenzyl)-10-methyl-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo2,3-c!quinoline,5-(2,4-dimethoxybenzyl)-10-methyl-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo2,3-c!quinoline,7-bromo-5-(2,4-dimethoxybenzyl)-10-methyl-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo2,3-c!quinoline,6-ethoxy-5-(3,4-dimethoxybenzyl)-10-methyl-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo2,3-c!quinoline,7-nitro-6-(3,4-dimethoxybenzyl)-10-methyl-2,3,4,4a,5,6,7,10c-octahydro-1H-indolo2,3-c!quinoline,7-(3,4-dimethoxybenzyl)-10-methyl-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo2,3-c!quinoline,7-nitro-6-(3,4-diethoxybenzyl)-10-methyl-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo2,3-c!quinoline, 6-methyl-8-bromo-1-(3,4-dimethoxyphenyl)-10-methyl-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo2,3-c!quinoline,7-(1,1-dimethylethyl)-5-(1-naphthalenyl-1-ethyl)-1,2,3,4,4a,5,6,10c-pyrido3,4-b!indole hydrochloride,7-methyloxy-1-(2-methylaminonaphthalenyl)-1-ethyl)-1,2,3,4,4a,5,6,10c-octahydrocyclopentaa!pyrido 3,4-b!indole, (Z) 2-butenedioate,6-(1,1-dimethylethyl)-1-(1-(3-diethylaminonaphthalenyl)-1-ethyl)-1,2,3,4,4a,5,6,10c-octahydrocyclopentaa!pyrido 3,4-b!indole hydrochloride, and 6-methyl-5-(4-dimethylamino-naphthalenyl)methyl!-1,2,3,4,4a,5,6,10c-octahydrocyclopentaa!pyrido 3,4-b!indole dihydrochloride.

Examples of compounds of Formula II include but are not limited to:

3-(2-amino-cyclopentyl)-6,7-dimethylindole,3-(2-amino-cyclopentyl)-5-methyl-7-bromoindole,3-(2-amino-cyclopentyl)-6-methyl-7-chloroindole,3-(2-amino-cyclopentyl)-6-bromo-7-methylindole,3-(2-amino-cyclopentyl)-benz(G)indole,3-(2-amino-cyclohexyl)-5-methyl-7-chloroindole,3-(2-amino-cyclohexyl)-7-chloroindole,3-(2-amino-cyclopropyl)-7-methoxyindole,3-(2-amino-cycloheptyl)-7-fluoroindole,3-(2-amino-cyclohexyl)-7-bromoindole,3-(2-amino-cyclopropyl)-6-methyl-7-bromoindole,3-(2-amino-cyclopentyl)-5-fluoro-7-methoxyindole,3-(2-amino-cyclopentyl)-5-nitro-7-chloroindole,3-(2-amino-cyclooctyl)-2-ethyl-7-fluoroindole, and3-(2-amino-cycloheptyl)-2-methyl-7-fluoroindole.

The present invention contemplates racemic mixtures as well as thesubstantially pure stereoisomers of the compounds of Formulas I and II.The term "enantiomer" is used herein as commonly used in organicchemistry to denote a compound which rotates the plane of polarization.Thus, the "- enantiomer" rotates the plane of polarized light to theleft, and contemplates the levorotary compound of Formulas I and V.The + and - enantiomers can be isolated using well-known classicalresolution techniques. One particularly useful reference which describessuch methods is JACQUES et. al. ENANTIOMERS, RACEMATES, AND RESOLUTIONS(John Wiley and Sons 1981). Appropriate resolution methods includedirect crystallization, entrainment, and crystallization by opticallyactive solvents. Chrisey, L. A. Heterocycles, 267:30 (1990). A preferredresolution method is crystallization with an optically active acid or bychiral synthesis as described in Example 46 using the method of A. I.Meyers. Loewe, M. F. et al., Tetrahedron Letters, 3291:26 (1985),Meyers, A. I. et al., J. Am. Chem. Soc., 4778:110 (1988). Preferredoptically active acids include camphorsulfonic and derivatives oftartaric acid.

The present invention encompasses both the R and the S configurations.The terms "R" and "S" are used herein as commonly used in organicchemistry to denote the specific configuration of a chiral center. See,R. T. Morrison and R. N. Boyd, Organic Chemistry, pp 138-139 (4th Ed.Allyn & Bacon, Inc., Boston) and Orchin, et al. The Vocabulary ofOrganic Chemistry, p. 126, (John Wiley and Sons, Inc.). Thus the presentinvention encompasses both the cis and trans conformation of eachparticular compound.

The compounds of the present invention are known to form hydrates andsolvates with appropriate solvents. Preferred solvents for thepreparation of solvate forms include water, alcohols, tetrahydrofuran,DMF, and DMSO. Preferred alcohols are methanol and ethanol. Otherappropriate solvents may be selected based on the size of the solventmolecule. Small solvent molecules are preferred to facilitate thecorresponding solvate formation. The solvate or hydrate is typicallyformed in the course of recrystallization or in the course of saltformation. One useful reference concerning solvates is Sykes, Peter, AGuidebook to Mechanism in Organic Chemistry, 6:56 (1986, John Wiley &Sons, New York). The term "solvate" as used herein includes hydrateforms such as monohydrate and dihydrates.

The compounds of the present invention can be prepared using chemicalprocesses that are understood in the art; however, a most preferredmethod for preparing the compounds of Formulas I and II is illustratedby Scheme I ##STR7## wherein R³² is independently selected from C₁ -C₆alkyl; R³⁰, R³¹, A, and Q are defined supra.

Further, compounds of Example 19 can be prepared as illustrated by thefollowing Scheme II: ##STR8## compounds of Example 20 can be prepared asillustrated by the following Scheme III: ##STR9##

The following Examples further illustrate the preparation of certain ofthe Formula I and II compounds. The examples are illustrative only, andare not intended to limit the scope of the invention.

The column chromatography procedures used standard flash chromotagraphytechniques. One well-known reference describing appropriate flashchromotagraphy techniques is Still, W. C. Kahn, and Mitra, J. Org.Chem., 43, 2932, (1978). Fractions containing product were generallyevaporated under reduced vacuum to provide the product.

Optical rotations were obtained using methanol, pyridine, or othersuitable solvent.

The hydrochloride salt of the particular compound was prepared byplacing the free base into diethyl ether containing an alcohol such asmethanol or other suitable solvent mixture. While stirring this ethersolution, a solution of HCl in diethyl ether was added dropwise untilthe solution became acidic. Alternatively, the ether solution wastreated with dry HCl gas.

The maleate salt of the particular compound was prepared by placing thefree base in ethyl acetate or other suitable solvent and treating withmaleic acid. The precipitate formed was filtered and dried to providethe corresponding hydrochloride or maleate salt of the free base.

For Examples 1 through 20, where applicable, diethylether was distilledfrom sodium benzophenone ketyl prior to use. All reactions wereperformed under a positive pressure of argon. ¹ H-NMR and ¹³ C-NMR datawere recorded on a Bruker AC-200P (200 MHz). IR spectra were obtained onNicolet 510 P-FT (film and KBr). Melting points were determined on aBuchi apparatus and are not corrected. Analytical TLC was performed onMerck TLC glass plates precoated with F₂₅₄ silica gel 60 (UV, 254 nm andIodine). Chromatographic separations were performed by using 230-400mesh silica gel (Merck). N-BOC-aziridines (2a-d) were prepared from thecorresponding alkenes following standard procedures.

Preparation 1 Indole starting materials

The indole starting materials (1a, 1b, and 1c) infra. were purchased(1a), prepared according to Bartoli's procedure (1b) Bartoli, G. et al.Tetrahedron Lett., 1989, 30, 2129! or (1c) synthesized from2-iodo-4,6-dimethylaniline (5'"). The process is illustrated by thefollowing Scheme IV: ##STR10##

The 2-Iodo-4,6-dimethylaniline (5'") synthesis can be completed asfollows: To a suspension of 5'" (24 mmol.), CuI (0.05 equiv.) and(PPh₃)₂ PdCl₂ (0.05 equiv.) in 30 ml of dry triethylamine under Aratmosphere was added trimethylsilylacetylene (1.1 equiv.) and theresulting mixture was stirred for 3 hours. Then, the solvent waseliminated under vacuum and the residue purified by flash chromatographyusing hexane/ethyl acetate (3:1) as eluent to yield 6' in quantitativeyield. A slurry of 6'" (23 mmol.) and CuI (2 equiv.) in 50 ml of drydimethylformamide was heated for 2.5 h. under Ar atmosphere at 100° C.After cooling down to room temperature the reaction mixture was filteredoff and the solid washed twice with ether (20 ml.). The organic phasewas washed with water (3×50 ml.), dried over Na₂ SO₄ and the solventevaporated to dryness. The crude product was purified by flashchromatography using hexane/ethyl acetate (3:1) as eluent to afford 1c(1.5 g., 45%).

The process for preparing compounds of Examples 1 through 18 isillustrated by the following Scheme: ##STR11##

EXAMPLE 1 Trans-3-(2-amino-cyclopentyl)-5-methylindole, hydrochloride

To a suspension of the corresponding indole 1a (5 mmol.) in 10 ml ofanhydrous ether under Ar atmosphere was added a 3M solution ofmethylmagnesium bromide (1.5 equiv.). The resulting mixture was stirredfor 45 min. at room temperature. Then, this mixture was cannulated to aslurry of Copper (I) bromide-dimethylsulfide complex (0.2 equiv.) in 5ml. of dry ether under Ar atmosphere at -30° C. The reaction mixture wasstirred for 30 min. at the same temperature. After this time the mixturewas cooled down to -78° C. and the corresponding aziridine 2a (1.5equiv.) dissolved in 10 ml. of dry ether was added. The whole mixturewas allowed to reach room temperature and stirring was kept overnight.The reaction was quenched with 10 ml. of a saturated solution ofammonium chloride. The layers were separated and the aqueous phase wasextracted with ether/ethyl acetate (1:1) (2×10 ml.). The combinedorganic extracs were dried over anhydrous sodium sulfate, the solventwas eliminated under vacuum and the residue was purified by flashchromatography using hexane/ethyl acetate (3:1). The corresponding N-BOCprotected tryptamine was dissolved in dichloromethane/ether. Thesolution was saturated with dry hydrogen chloride and stirred overnightat room temperature. Finally, the solvent was evaporated and the crudetitle tryptamines purified by washing with dichoromethane/ether/methanolmixture (2:3:1). The product was identified as the title compound (3a).

Yield: 85%. Mp: >200° C. ¹ H NMR (CD₃ OD), δ: 7.35 (s,1H), 7.23-7.12 (m,2H), 6.91 (d, J=7.5 Hz, 1H), 3.73 (m, 1H), 3.27 (m, 1H), 2.38-2.10 (m,5H), 2.05-1.70 (m, 4H). ¹³ C NMR (CD₃ OD), δ: 136.98, 128.93, 127.84,124.27, 123.13, 119.01, 114.19, 112.37, 58.56, 43.93, 33.10, 31.30,23.07, 21.73. IR (KBr): 3304, 2963, 1593, 1510, 1481, 800 cm⁻¹. MS (EI):214 (M⁺ -HCl, 28), 197 (70), 170 (14), 144 (42), 126 (49), 105 (33), 84(100).

EXAMPLE 2 Trans-3-(2-amino-cyclopentyl)-7-chloroindole, hydrochloride

The title compound (3b) was prepared using substantially the sameprocedure as described by Example 1; however, the indole startingmaterial was a compound of Formula 1b.

Yield: 37%. Mp: >200° C. ¹ H NMR (CD₃ OD), δ: 7,56 (d, J=7.7 Hz, 1H),7.31 (s, 1H), 7.12 (d J=7.3 Hz, 1H), 7.01 (t, J=7.8 Hz, 1H), 3.77 (q,J=7.9 Hz, 1H), 3.40-3.25 (m, 1H), 2.40-2.15 (m, 2H), 2.05-1.70 (m, 4H).¹³ C NMR (CD₃ OD), δ: 135.48, 129.53, 124.28, 122.13, 120.79, 118.40,118.02, 116.18, 58.55, 43.79, 33.32, 31.36, 23.11. IR (KBr): 3422, 3298,3040, 2972, 2909, 1495 cm⁻¹. MS (EI): 235 (M⁺ -Cl, 100), 218 (28), 165(7).

EXAMPLE 3 Trans-3-(2-amino-cyclohexyl)-5-methylindole, hydrochloride

The title compound (3d) was prepared using substantially the sameprocedure as described by Example 1.

Yield: 80%. Mp: >200° C. ¹ H NMR (CD₃ OD), δ: 7,44 (s, 1H), 7.27 (d,J=8.3 Hz, 1H), 7.18 (s, 1H), 6.95 (dd, J=8.3 and 1.2 Hz, 1H), 3.55-3.40(m, 1H), 2.86 (dt, J=4.3 and 11.3 Hz, 1H), 2.42 (s, 3H), 2.25-2.12 (m,1H), 2.10-1.79 (m, 4H), 1.75-1.40 (m, 3H). ¹³ C NMR (CD₃ OD), δ: 136.97,129.12, 127.74, 124.42, 123.73, 119.09, 114.77, 112.48, 56.22, 41.61,34.75, 32.42, 26.93, 25.79, 21.73. IR (KBr): 3400, 3283, 3021, 2936,2861, 1491 cm⁻¹. MS (EI): 229 (M⁺ -Cl, 100).

EXAMPLE 4 Trans-3-(2-amino-cyclohexyl)-7-chloroindole, hydrochloride(3e)

The title compound (3e) was prepared using substantially the sameprocedure as described by Example 1.

Yield: 43%. Mp: >200° C. ¹ H NMR (CD₃ OD), δ: 7,63 (d, J=7.8 Hz, 1H),7.35 (s, 1H), 7.14 (d, J=7.4 Hz, 1H), 7.02 (t, J=7.7 Hz, 1H), 3.60-3.40(s, 1H), 3.08-2.91 (m, 1H), 2.30-2.10 (m, 1H), 2.05-1.80 (m, 4H),1.75-1.45 (m, 3H). ¹³ C NMR (CD₃ OD), δ: 135.43, 129.41 125.00, 122.15,120.87, 118.53, 118.09, 116.70, 56.12, 41.43, 34.74, 32.37, 26.80,25.68. IR (KBr): 2938, 2859, 1429, 1341, 779, 735 cm ⁻¹. MS (EI): 249(M⁺ -Cl, 100).

EXAMPLE 5 Trans-3-(2-amino-cyclopentyl)-5,7-dimethylindole,hydrochloride

The title compound (3f) was prepared using substantially the procedureof Example 1; however, the indole was 1c and the aziridine was 2b.

Yield: 45%. Mp: >200° C. ¹ H NMR (CD₃ OD), δ: 7,27 (s, 1H), 7.19 (s,1H), 6.77 (s, 1H), 3.42 (dt, J=11.0 and 4.2 Hz, 1H), 2.85 (dt, J=11.4and 4.2 Hz, 1H), 2.44 (s, 3H), 2.39 (s, 3H), 2.30-2.10 (m, 1H),2.08-1.83 (m, 4H), 1.70-1.40 (m, 3H). ¹³ C NMR (CD₃ OD), δ: 136.39,129.37, 127.39, 125.01, 123.56, 121.94, 116.78, 115.16, 56.28, 41.70,34.71, 32.40, 26.93, 25.80, 21.72, 16.93. IR (KBr): 3420, 3279, 3013,2934, 2861, 1505 cm⁻¹. MS (EI): 242 (M⁺ -HCl, 62), 225 (25), 199 (23),184 (20), 171 (38), 158 (100), 145 (18), 128 (12), 115 (12), 97 (12).

Substantially the same procedure was used to prepareTrans-3-(2-amine-cyclopentyl)-5,7-dimethylindole, hydrochloride (3c);however, the aziridine was 2a.

Yield: 63%. ¹ H NMR (DMSO-d₆), δ: 10.8 (s, 1H), 8.12 (broad s, 3H),7.30-7.20 (m, 2H), 6.70 (s, 1H), 3.70-3.55 (m, 1H), 3.55-3.20 (m, 1H),2.38 (s, 3H), 2.36 (s, 3H), 2.30-2.10 (m, 2H), 2.00-1.60 (m, 4H).

EXAMPLE 6 Trans-10-methyl-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo2,3-c!quinoline, hydrochloride

A suspension of tryptamine hydrochloride (3a) (1.3 mmol.) in 10 ml. ofdistilled water was dissolved by heating. To this solution glyoxylicacid (1.43 mmol.) in 1 ml. of water was added. Subsequently, a solutionof KOH (1.3 mmol.) in 1 ml. of distilled water was slowly added to reachpH=4. The resulting solution was stirred at room temperature for 1 h.After this time, commercially available hydrochloric acid (0.5 ml.) wasadded dropwise and the resulting mixture was refluxed for 30 min.Another portion of hydrochloric acid (0.5 ml.) was added and thereaction further refluxed for 15 min. Finally, the reaction mixture wascooled down to room temperature and filtered off. The titletetrahydro-b-carboline (4a) was subsequently washed with water andethanol.

Yield: 81%. Mp: >200° C. ¹ H NMR (DMSO-d₆), δ: >11.0 (s, 1H), 9.92(broad s, 1H), 9.68 (broad s, 1H), 7.38 (s, 1H), 7.23 (d, J=8.3 Hz, 1H),6.88 (d, J=7.8 Hz, 1H), 4.50-4.22 (m, 2H), 3.18-2.95 (m, 2H), 2.80-2.65(m, 1H), 2.34 (s, 3H), 2.30-2.15 (m, 1H), 1.98-1.80 (m, 2H), 1.80-1.20(4H). ¹³ C NMR (DMSO-d₆), δ: 134.75 127.31, 126.49, 125.64, 122.65,119.11, 111.14, 108.82, 58.99, 37.18, 29.42, 28.84, 24.94, 24.43, 21.28.IR (KBr): 3391, 3266, 2936, 2861, 2801, 2762 cm⁻¹. MS (EI): 241 (M⁺ -Cl,100).

EXAMPLE 7 Trans-8-chloro-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo2,3-c!quinoline, hydrochloride (4b)

A suspension of tryptamine hydrochloride (3b) (1.3 mmol.) in 10 ml. ofdistilled water was dissolved by heating. To this solution glioxylicacid (1.43 mmol.) in 1 ml. of water was added. Subsequently, a solutionof KOH (1.3 mmol.) in 1 ml. of distilled water was slowly added to reachpH=4. The resulting solution was stirred at room temperature for 1 h.After this time, commercially available hydrochloric acid (0.5 ml.) wasadded dropwise and the resulting mixture was refluxed for 30 min.Another portion of hydrochloric acid (0.5 ml.) was added and thereaction further refluxed for 15 min. Finally, the reaction mixture wascooled down to room temperature and filtered off. The titletetrahydro-b-carboline (4b) was subsequently washed with water andethanol.

Yield: 45%. Mp: >200° C. ¹ H NMR (DMSO-d₆), δ: >11.0 (s, 1H), 10.05(broad s, 1H), 9.87 (broad s, 1H), 7.58 (d, J=7.8 Hz, 1H), 7.16 (d,J=7.6 Hz, 1H), 6.98 (t, J=7.9 Hz, 1H), 4.60-4.20 (m, 2H), 3.18-2.95 (m,2H), 2.90-2.70 (m, 1H), 2.25-2.18 (m, 1H), 1.98-1.75 (m, 2H), 1.65-1.20(4H). ¹³ C NMR (DMSO-d₆), δ: 133.17 128.18, 127.23, 120.65, 120.03,118.55, 115.78, 110.73, 58.74, 36.93, 29.16, 28.77, 24.88, 24.36. IR(KBr): 3422, 3231, 2936, 2861, 2760, 1429 cm⁻¹. MS (EI): 261 (M⁺ -Cl,30), 241 (100).

EXAMPLE 8Trans-5-(3,4-dimethoxybenzyl)-9-methyl-1,2,3,4,4a,5,6,10c-octahydrocyclopentaa!pyrido 3,4-b!indole, hydrochloride (4c)

A suspension of the corresponding tryptamine hydrochloride (3a) (1 mmol)and the correponding 4-alkylidene-2-methyloxazolin-5-one (1.2 mmol) in1N hydrochloric acid (3 ml.) was refluxed under Ar atmosphere during 72h. After this time the reaction mixture was allowed to reach roomtemperature and filtered off. The crude solid was purified by flashchromatography using dichloromethane/methanol (9:1) as eluent.

Yield: 88%. Mp: 187°-191° C. ¹ H NMR (DMSO-d₆), δ: >11.0 (s, 1H), 10.38(broad s, 1H), 9.25 (broad s, 1H), 7.50-7.15 (m, 3H), 7.15-6.80 (m, 3H),5.0-4.70 (broad s, 1H), 3.75 (s, 6H), 3.40-2.80 (m), 2.49 (s, 3H),2.20-1.70 (m, 4H), 1.55-1.30 (broad s, 1H). ¹³ C NMR (DMSO-d₆), δ:148.73 147.90, 134.45, 130.24, 128.17, 127.64, 125.44, 123.03, 121.78,118.43, 113.69, 111.95, 111.27, 110.64, 62.01, 57.50, 55.51, 37.49,25.52, 25.14, 21.30, 20.73. IR (KBr): 3438, 3237, 2942, 1518, 1264, 1248cm⁻¹. MS (EI): 377 (M⁺ -Cl, 100).

EXAMPLE 9Trans-7-chloro-5-(3,4-dimethoxybenzyl)-1,2,3,4,4a,5,6,10c-octahydrocyclopentaa!pyrido 3,4-b!indole, hydrochloride (4d)

A suspension of the corresponding tryptamine hydrochloride (3b) (1 mmol)and the correponding 4-alkylidene-2-methyloxazolin-5-one (1.2 mmol) in1N hydrochloric acid (3 ml.) was refluxed under Ar atmosphere during 72h. After this time the reaction mixture was allowed to reach roomtemperature and filtered off. The crude solid was purified by flashchromatography using dichloromethane/methanol (9:1) as eluent.

Yield: 52%. Mp: >230° C. dec. ¹ H NMR (DMSO-d₆), δ: >11.0 (s, 1H), 10.40(broad s, 1H), 9.30 (broad s, 1H), 7.60-7.42 (m, 1H), 7.38-6.90 (m, 5H),4.90-4.75 (broad s, 1H), 3.78 (s, 3H), 3.76 (s, 3H), 3.40-3.00 (m),2.15-1.80 (m, 4H), 1.60-1.35 (broad s, 1H). ¹³ C NMR (DMSO-d₆), δ:148.70, 147.91, 132.95, 131.78, 128.25, 127.02, 121.75, 121.11, 120.41,117.96, 116.05, 113.54, 112.72, 111.99, 61.74, 57.45, 55.50, 37.27,25.24, 25.07, 20.77. IR (KBr): 3588, 3438, 1518, 1290 cm⁻¹. MS (EI): 398(M⁺ +2-HCl, 40), 396 (M⁺ -HCl, 100).

EXAMPLE 10Trans-5-(3,4-dimethoxybenzyl)-7,9-dimethyl-1,2,3,4,4a,5,6,10c-octahydrocyclopentaa!pyrido 3,4-b!indole, hydrochloride (4e)

A suspension of the corresponding tryptamine hydrochloride (3c) (1 mmol)and the correponding 4-alkylidene-2-methyloxazolin-5-one (1.2 mmol) in1N hydrochloric acid (3 ml.) was refluxed under Ar atmosphere during 72h. After this time the reaction mixture was allowed to reach roomtemperature and filtered off. The crude solid was purified by flashchromatography using dichloromethane/methanol (9:1) as eluent.

Yield: 87%. Mp: >200° C. ¹ H NMR (DMSO-d₆), δ: >11.0 (s, 1H), 10.20(broad s, 1H), 9.20 (broad s, 1H), 7.29 (s, 1H), 7.20-6.95 (m, 3H), 6.75(s, 1H), 4.90-4.70 (broad s, 1H), 3.78 (s, 6H), 3.30-2.90 (m), 2.48 (s,3H), 2.34 (s, 3H), 2.10-1.70 (m, 4H), 1.60-1.30 (broad s, 1H). ¹³ C NMR(DMSO-d₆), δ: 148.73, 147.90, 134.01, 129.98, 128.31, 127.84, 125.10,123.82, 121.75, 120.42, 116.03, 113.58, 111.99, 111.21, 61.94, 57.62,55.52, 37.60, 25.57, 25.17, 21.23, 20.75, 17.07. IR (KBr): 3447, 2910,1520 cm⁻¹. MS (EI): 391 (M⁺ -Cl, 100), 239 (35).

EXAMPLE 11Trans-6-(3,4-dimethoxybenzyl)-10-methyl-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo2,3-c!quinoline, hydrochloride (4f)

A suspension of the corresponding tryptamine hydrochloride (3d) (1 mmol)and the correponding 4-alkylidene-2-methyloxazolin-5-one (1.2 mmol) in1N hydrochloric acid (3 ml.) was refluxed under Ar atmosphere during 72h. After this time the reaction mixture was allowed to reach roomtemperature and filtered off. The crude solid was purified by flashchromatography using dichloromethane/methanol (9:1) as eluent.

Yield: 85%. Mp: 197°-200° C. ¹ H NMR (DMSO-d₆), δ: >11.0(s, 1H), 8.90(broad s, 1H), 7.42 (s, 1H), 7.28 (d, J=8.3 Hz, 1H), 7.16 (s, 1H),7.05-6.90 (m, 3H), 4.95-4.80 (broad s, 1H), 3.73 (s, 6H), 3.66-3.59 (m,1H), 3.25-2.80 (m, 4), 2.35 (s, 3H), 2.20-2.10 (m, 1H), 1.95-1.20 (m,6H). ¹³ C NMR (DMSO-d₆), δ: 148.67, 147.91, 134.92, 134.76, 129.72,127.85, 127.45, 125.43, 122.91, 121.85, 119.43, 113.59, 111.90, 111.30,109.45, 59.98, 55.47, 55.40, 37.08, 36.65, 29.48, 28.24, 24.94, 24.41,21.32. IR (KBr): 3439, 2936, 1516, 1464, 1453, 1265 cm⁻¹. MS (EI): 391(M⁺ -Cl, 100).

EXAMPLE 12Trans-8-chloro-6-(3,4-dimethoxybenzyl)-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo2,3-c!quinoline, hydrochloride (4g)

A suspension of the corresponding tryptamine hydrochloride (3e) (1 mmol)and the correponding 4-alkylidene-2-methyloxazolin-5-one (1.2 mmol) in1N hydrochloric acid (3 ml.) was refluxed under Ar atmosphere during 72h. After this time the reaction mixture was allowed to reach roomtemperature and filtered off. The crude solid was purified by flashchromatography using dichloromethane/methanol (9:1) as eluent.

Yield: 47%. Mp: >250° C. ¹ H NMR (DMSO-d₆), δ: >11.0 (s, 1H), 9.75(broad s, 1H), 8.90 (broad s, 1H), 7.64 (d, J=7.9 Hz, 1H), 7.20 (d,J=7.8 Hz 1H), 7.15-7.00 (m, 4H), 4.90-4.80 (broad s, 1H), 3.74 (s, 6H),3.70-3.60 (m, 1H), 3.25-2.85 (m, 4H), 2.20-2.15 (m, 1H), 1.95-1.25 (m,6H). ¹³ C NMR (DMSO-d₆), δ: 148.72, 148.00, 133.46, 131.35, 128.00,127.08, 121.86, 121.13, 120.28, 119.01, 115.99, 113.41, 111.98, 111.66,59.62, 55.53, 55.42, 54.98, 37.24, 36.49, 29.23, 28.25, 24.88, 24.34. IR(KBr): 3428, 2938, 1518, 1250 cm⁻¹. MS (EI): 410 (M⁺ -HCl, 100).

EXAMPLE 13Trans-6-(3,4-dimethoxybenzyl)-8,10-dimethyl-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo2,3-c!quinoline, hydrochloride (4h)

A suspension of the corresponding tryptamine hydrochloride (3f) (1 mmol)and the correponding 4-alkylidene-2-methyloxazolin-5-one (1.2 mmol) in1N hydrochloric acid (3 ml.) was refluxed under Ar atmosphere during 72h. After this time the reaction mixture was allowed to reach roomtemperature and filtered off. The crude solid was purified by flashchromatography using dichloromethane/methanol (9:1) as eluent.

Yield: 78%. Mp: 198°-202° C. ¹ H NMR (DMSO-d₆), δ: 10.88 (s, 1H), 9.81(broad s, 1H), 8.78 (broad s, 1H), 7.24 (s, 1H), 7.20 (s, 1H), 7.10-6.90(m, 2H), 6.73 (s, 1H), 4.90-4.75 (broad s, 1H), 3.74 (s, 6H), 3.25-3.10(m, 2H), 3.10-2.80 (m, 2H), 2.45 (s, 3H), 2.32 (s, 3H), 2.20-2.10 (m,1H), 2.00-1.80 (m, 3H), 1.60-1.10 (m, 3H), ¹³ C NMR (DMSO-d₆), δ: 148.65147.87, 134.44, 129.55, 128.17, 127.59, 125.13, 123.68, 121.90, 120.36,117.05, 113.64, 111.89, 110.04, 59.89, 55.78, 55.41, 37.17, 36.56,29.47, 28.21, 24.94, 24.43, 21.26, 17.09. IR (KBr): 3450, 2936, 1516,1493, 1264, 1240 cm⁻¹. MS (EI): 405 (M⁺ -Cl, 100).

EXAMPLE 14Trans-7-(3,4-dimethoxybenzyl)-11-methyl-1,2,3,4,5,5a,6,7,8,12a-decahydrocycloheptaa!pyrido 3,4-b!indole, hydrochloride (4i)

A suspension of the corresponding tryptamine hydrochloride (3g) (1 mmol)and the correponding 4-alkylidene-2-methyloxazolin-5-one (1.2 mmol) in1N hydrochloric acid (3 ml.) was refluxed under Ar atmosphere during 72h. After this time the reaction mixture was allowed to reach roomtemperature and filtered off. The crude solid was purified by flashchromatography using dichloromethane/methanol (9:1) as eluent.

Yield: 35%. Mp: 187°14 190° C. ¹ H NMR (DMSO-d₆), δ: >11.0 (s, 1H), 9.66(broad s, 1H), 7.29-7.25 (m, 2H), 6.92 (d, J=7.8 Hz, 1H), 6.81 (d, J=8.2Hz, 1H), 6.65-6.56 (m, 2H) 4.80-4.70 (broad s, 1H), 3.66 (s, 3H), 3.43(s, 3H), 3.00-2.90 (m, 1H), 2.90-2.70 (m, 1H), 2.35 (s, 3H), 2.35-2.20(m, 1H), 1.80-1.30 (m, 8H), 0.85-0.65 (m, 1H). ¹³ C NMR (DMSO-d₆), δ:148.56 147.96, 135.12, 128.81, 128.05, 127.27, 125.32, 123.09, 121.73,118.97, 113.32, 111.85, 111.31, 110.51, 55.60, 55.08, 54.97, 51.48,36.97, 36.24, 32.74, 31.88, 26.37, 24.88, 24.14, 21.30. IR (KBr): 3414,3343, 2932, 2859, 1516, 1265 cm⁻¹. MS (EI): 405 (M⁺ -Cl, 100), 335 (20).

EXAMPLE 15Trans-9-methyl-5-(1-naphthylmethyl)-1,2,3,4,4a,5,6,10c-octahydrocyclopentaa!pyrido3,4-b!indole, hydrochloride (4j)

A suspension of the corresponding tryptamine hydrochloride (3a) (1 mmol)and the correponding 4-alkylidene-2-methyloxazolin-5-one (1.2 mmol) in1N hydrochloric acid (3 ml.) was refluxed under Ar atmosphere during 72h. After this time the reaction mixture was allowed to reach roomtemperature and filtered off. The crude solid was purified by flashchromatography using dichloromethane/methanol (9:1) as eluent.

Yield: 78%. Mp: >200° C. ¹ H NMR (DMSO-d₆), δ: >11.0 (s, 1H), 10.45(broad s, 1H), 9.03 (broad s, 1H), 8.46 (d, J=7.9 Hz, 1H), 8.12-7.90 (m,3H), 7.70-7.40 (m, 3H), 7.40-7.25 (m, 2H), 6.96 (d, J=8.0 Hz, 1H),5.15-4.90 (broad s, 1H), 4.45-4.30 (m, 1H), 3.65-3.50 (m), 3.15-2.95 (m,1H), 2.38 (s, 3H), 2.00-1.70 (m, 4H), 1.60-1.35 (broad s, 1H). ¹³ C NMR(DMSO-d₆), δ: 134.59, 133.86, 131.63, 131.32, 129.92, 129.18, 128.86,128.07, 127.74, 126.38, 125.96, 125.83, 125.48, 124.08, 123.20, 118.52,111.31, 110.97, 61.78, 55.76, 37.40, 35.13, 25.49, 25.12, 21.32, 20.67.IR (KBr): 3445, 3231, 2949, 2878, 2780, 793 cm⁻¹. MS (EI): 367 (M⁺ -Cl,100).

EXAMPLE 16Trans-10-methyl-6-(1-naphthylmethyl)-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo2,3-c!quinoline, hydrochloride (4k)

A suspension of the corresponding tryptamine hydrochloride (3d) (1 mmol)and the correponding 4-alkylidene-2-methyloxazolin-5-one (1.2 mmol) in1N hydrochloric acid (3 ml.) was refluxed under Ar atmosphere during 72h. After this time the reaction mixture was allowed to reach roomtemperature and filtered off. The crude solid was purified by flashchromatography using dichloromethane/methanol (9:1) as eluent.

Yield: 80%. Mp: >200° C. ¹ H NMR (DMSO-d₆), δ: >11.0 (s, 1H), 8.40 (d,J=7.8 Hz, 1H), 8.01 (d, J=7.5 Hz, 1H), 7.92 (d, J=8.2 Hz, 1H), 7.74 (d,J=6.8 Hz, 1H), 7.70-7.40 (m, 4H), 7.35 (d, J=8.4 Hz, 1H), 6.97 (d, J=8.2Hz, 1H), 5.15-4.90 (broad s, 1H), 4.50-4.30 (m, 1H), 3.50-3.10 (m, 2H),3.10-2.82 (m, 2H), 2.38 (s, 3H), 2.10-1.20 (m, 7H). ¹³ C NMR (DMSO-d₆),δ: 135.05, 134.90, 133.85, 131.79, 131.28, 129.36, 128.93, 128.07,127.56, 126.33, 125.94, 125.83, 125.41, 124.02, 123.10, 119.54, 111.27,109.61, 59.72, 53.97, 36.73, 35.27, 29.47, 28.37, 24.92, 24.36, 21.34.IR (KBr): 3447, 3235, 2936, 2857, 1450, 790 cm⁻¹. MS (EI): 381 (M⁺ -Cl,100).

EXAMPLE 17Trans-8,10-dimethyl-6-(1-naphthylmethyl)-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo2,3-c!quinoline, hydrochloride (4l)

A suspension of the corresponding tryptamine hydrochloride (3f) (1 mmol)and the correponding 4-alkylidene-2-methyloxazolin-5-one (1.2 mmol) in1N hydrochloric acid (3 ml.) was refluxed under Ar atmosphere during 72h. After this time the reaction mixture was allowed to reach roomtemperature and filtered off. The crude solid was purified by flashchromatography using dichloromethane/methanol (9:1) as eluent.

Yield: 77%. Mp: >200° C. ¹ H NMR (DMSO-d₆), δ: >11.0 (s, 1H), 10.11(broad s, 1H), 8.52 (d, J=8.2 Hz, 1H), 8.35 (broad s, 1H), 8.02 (d,J=7.3 Hz, 1H), 7.92 (d, J=7.9 Hz, 1H), 7.82 (d, J=6.9 Hz, 1H), 7.71-7.46(m, 3H), 7.29 (s, 1H), 6.78 (s, 1H), 5.10-4.90 (broad s, 1H), 4.70-4.50(m, 1H), 3.40-3.20 (m, 2H), 3.10-2.80 (m, 2H), 2.51 (s, 3H), 2.34 (s,3H), 2.05-1.90 (m, 1H), 1.80-1.70 (m, 2H), 1.60-1.20 (m, 4H). ¹³ C NMR(DMSO-d₆), δ: 134.57, 133.87, 131.95, 131.42, 129.29, 129.11, 128.81,128.04, 127.71, 126.21, 125.91, 125.83, 125.14, 124.46, 123.91, 120.46,117.14, 110.25, 59.65, 54.03, 36.66, 35.25, 29.47, 28.32, 24.94, 24.35,21.26, 17.30. IR (KBr): 3449, 2934, 2859, 2791, 1449, 779 cm⁻¹. MS (EI):395 (M⁺ -Cl, 100).

EXAMPLE 18 Trans-spiro-6,6-2-(3,4-dimethoxy)-1,2,3,4-tetrahydronaphthyl!-10-methyl-2,3,4,4a,5,6,7,11a-octahydro-1H-indolo2,3-c!quinidine, hydrochloride (4m)

A suspension of the corresponding tryptamine hydrochloride (3a) (1 mmol)and the corresponding 4-alkylidene-2-methyloxazolin-5-one (1.2 mmol) in1N hydrochloric acid (3 ml.) was refluxed under Ar atmosphere during 72h. After this time the reaction mixture was allowed to reach roomtemperature and filtered off. The crude solid was purified by flashchromatography using dichloromethane/methanol (9:1) as eluent.

Epimeric mixture. Yield: 89%. ¹ H NMR (DMSO-d₆), δ: >11.0 (s, 1H), 10.12(broad s, 1H), 8.72 (broad s, 1H), 7.42 (s, 1H), 7.21 (s, 1H), 6.90-6.60(s, 3H), 3.75 (s, 3H), 3.71 (s, 3H), 3.30-2.80 (m, 5H), 2.35 (s, 3H),2.00-1.20 (m, 6H). ¹³ C NMR (DMSO-d₆), δ: 147.44, 134.84, 134.32,133.98, 127.42, 126.53, 126.35, 125.25, 125.13, 123.60, 123.25, 122.98,119.56, 119.43, 112.05, 111.48, 111.27, 108.78, 108.60, 57.83, 57.50,56.07, 55.56, 36.40, 31.91, 30.74, 29.39, 29.21, 28.73, 28.41, 24.92,24.38, 23.83, 21.30. IR (KBr): 3440, 2950, 1518, 1200, 1110, cm⁻¹. MS(EI): 417 (M⁺ -Cl, 100).

EXAMPLE 19Trans-1-(3,4-dimethoxybenzyl)-3,4,6-trimethyl-1,2,3,4,-tetrahydro-9-pyrido3,4-b!indole,hydrochloride (4n)

Trans-3-(2-amine-1,2-dimethylethyl)-5-methylindole, hydrochloride (3h)was prepared using substantially the procedure of Example 1; however,the aziridine was 2c.

Yield: 71%. ¹ H NMR (CD₃ OD), δ: 7,45 (s, 1H), 7.32 (d, J=8.3 Hz, 1H),7.19 (s, 1H), 7.00 (dd, J=8.4 and 1.5 Hz, 1H), 3.66 (t, J=6.9 Hz, 1H),3.28 (t, J=7.3 Hz, 1H), 2.47 (s, 3H), 1.48 (d, J=7.2 Hz, 3H), 1.38 (d,J=6.6 Hz, 3H). ¹³ C NMR (CD₃ OD), δ: 136.89, 129.19, 127.68, 124.46,123.69, 119.09, 115.41, 112.44, 53.51, 36.62, 21.71, 17.06, 16.49.

A suspension of the corresponding tryptamine hydrochloride (3h) (1 mmol)and 6,7-dimethoxytetralin-2-one (1.2 mmol) in 1N hydrochloric acid (3ml.) was refluxed under Ar atmosphere during 72 h. After this time thereaction mixture was allowed to reach room temperature and filtered off.The crude solid was purified by flash chromatography usingdichloromethane/methanol (9:1) as eluent.

Yield: 32%. Mp: 195°-199° C. ¹ H NMR (DMSO-d₆), δ: >11.0 (s, 1H), 9.40(broad s, 1H), 8.90 (broad s, 1H), 7.40 (s, 1H), 7.30 (d, J=8.2 Hz, 1H),7.08 (s, 1H), 6.96-6.90 (m, 3H), 4.90-4.80 (broad s, 1H), 3.73 (s, 3H),3.72 (s, 3H), 3.70-3.60 (m, 2H), 3.20-3.00 (m, 3H), 2.37 (s, 3H), 1.46(broad s, 3H), 1.40 (broad s, 3H). ¹³ C NMR (DMSO-d₆), δ: 148.66,147.93, 135.00, 129.21, 127.40, 125.40, 122.97, 121.82, 119.07, 113.56,111.95, 111.24, 110.34, 57.32, 55.43, 55.33, 54.60, 36.46, 32.56, 21.24,17.06, 15.92. IR (KBr): 3438, 2936, 1518, 1464, 1265, 1242, 1040 cm⁻¹.MS (EI): 365 (M⁺ -Cl, 100).

EXAMPLE 20 Cis-3-(2-amine-cyclohexyl)-5-methylindole, hydrochlorideCis-6-(3,4-dimethoxybenzyl)-10-methyl-2,3,4,4a,5,6,7,11c-octahydro-1H-indolo2,3-c!quinoline, hydrochloride (4o)

The title compound (3i) was prepared following the procedure describedby Scmuszkovicz, J. et al. Tetrahedron, 1991, 47, 8653 starting from5-methylindole (1a).

Mp: 86°-90° C. ¹ H NMR (CD₃ OD), δ: 7,38 (s, 1H), 7.26 (d, J=8.3 Hz,1H), 7.11 (s, 1H), 6.96 (d, J=8.2, 1H), 3.90-3.70 (m, 1H), 3.55-3.38 (m,1H), 2.42 (s, 3H), 2.40-2.35 (m, 1H), 2.10-1.79 (m, 4H), 1.75-1.50 (m,3H). ¹³ C NMR (CD₃ OD), δ: 136.75, 129.27, 127.88, 124.63, 123.51,118.71, 114.49, 112.34, 52.60, 36.79, 29.52, 26.44, 25.85, 21.68, 21.00.IR (KBr): 3401, 3017, 2932, 2863, 1561, 1489 cm⁻¹. MS (EI): 229 (M⁺ -Cl,100).

The process for preparing the final product (4o) is illustrated by thefollowing Scheme: ##STR12##

Mp: 167°-171° C. ¹ H NMR (DMSO-d₆), δ: >11.0 (s, 1H), 8.87 (broad s,2H), 7.29-7.20 (m, 3H), 7.12-6.85 (m, 3H), 4.95-4.80 (broad s, 1H), 3.76(s, 3H), 3.75 (s, 3H), 3.70-3.60 (m), 3.25-3.00 (m, 1H), 2.36 (s, 3H),2.40-2.00 (m), 1.95-1.20 (m, 6H), ¹³ C NMR (DMSO-d₆), δ: 148.67 147.87,134.80, 128.71, 128.43, 127.63, 125.45, 123.32, 121.75, 117.82, 113.59,111.91, 111.30, 111.34, 56.99, 55.46, 55.12, 36.12, 36.65, 28.42, 27.49,24.94, 24.39, 21.23, 19.17. IR (KBr): 3439, 2934, 1516, 1263 cm⁻¹. MS(EI): 390 (M⁺ -ClH, 100).

As noted above, the compounds of the present invention are useful inblocking the effect of serotonin or other agonists at 5-HT_(2A),5-HT_(2B) and/or 5-HT_(1c) receptors. Thus, the present invention alsoprovides a method for blocking 5-HT_(2A), 5-HT_(2B) or 5-HT_(1c)receptors in mammals comprising administering to a mammal requiringblocking of a 5-HT_(2A), 5-HT_(2B) or 5-HT_(1c) receptor, respectively,a receptor blocking dose of a compound of the invention.

The term "receptor blocking dose", means an amount of compound necessaryto block a targeted receptor, selected from the group consisting of5-HT_(2A), 5-HT_(2B), and 5-HT_(1c) receptor in a mammal. The activecompounds are effective over a wide dosage range. For example, dosagesper day will normally fall within the range of about 0.05 to about 250mg/kg of body weight. In the treatment of adult humans, the range ofabout 0.5 to 100 mg/kg, in single or divided doses, is preferred. Theranges of about 5 mg/kg to about 60 mg/kg and about 10 mg/kg to about 50mg/kg are especially preferred. However, it will be understood that theamount of the compound actually administered will be determined by aphysician in light of the relevant circumstances, including thecondition to be treated, the choice of compound to be administered, theage, weight, and response of the individual patient, the severity of thepatient's symptoms, and the chosen route of administration, andtherefore the above dosage ranges are not intended to limit the scope ofthe invention in any way. The compounds may be administered by a varietyof routes such as oral, transdermal, subcutaneous, intranasal,intramuscular, and intravenous routes.

A variety of physiologic functions have been shown to be subject to beinfluenced by 5-HT_(1c) receptors. Therefore, the compounds of thepresent invention can be used to treat a variety of disorders in mammalsassociated with these receptors. Such disorders include sleepingdisorders, eating disorders, including bulimia and obesity,thermoregulation, sexual disorders, hyperactivity, excessive aggression,alcoholism, anxiety, obsessive-compulsive disorders, depression,schizophrenia and schizophreniform disorders, panic disorders, Gilles dela Tourette syndrome, migraine headaches, and Alzheimer's Disease.Additionally, effects of the 5-HT_(1c) receptor indicate that thecompounds of the present invention can be useful for relieving thesensation of pain. Thus, the present invention also provides methods fortreating the above disorders and for relieving the sensation of pain.

Several examples of more specific disorders which may be treated usingcompounds of this invention include, but are not limited to: (numeralsin parenthesis refer to the DSM-III-R Classification Codes)Attention-deficit hyperactivity disorder (314.01) conduct disorders(312.20, 312.00, 312.90), primary degenerative dementia of the Alzheimertype, senile onset (290.30, 290.20, 290.21, 290.00), primarydegenerative dementia of the Alzheimer type, presenile onset (290.11,290.12, 290.13, 290.10), alcohol withdrawal delirium (291.00), alcoholhallucinosis (291.30), alcohol, dementia associated with alcoholism(291.20), cannabis, delusional disorder (292.11), cocaine, intoxication(305.60), hallucinogen, mood disorder (292.84), nicotine withdrawal(292.00), phencyclidine or similarly acting arylcyclohexylamineintoxication (305.90), other psychoactive substance intoxication(305.90), delirium (293.00), dementia (294.10), organic delusionaldisorder (293.81), organic hallucinosis (293.82), organic mood disorder(293.83), organic anxiety disorder (294.80), organic personalitydisorder (310.10), organic mental disorder (294.80), schizophrenia,catatonic (295.21, 295.22, 295.23, 295.24, 295.25, 295.20),schizophrenia, disorganized (295.11, 295.12, 295.13, 295.14, 295.15,295.00), schizophrenia, paranoid (295.31, 295.32, 295.33, 295.34,295.35, 295.00), schizophrenia, undifferentiated (295.91, 295.92,295.93, 295.94, 295.95, 295.00), schizophrenia, residual (295.61,295.62, 295.63, 295.64, 295.65, 295.60), delusional (paranoid disorder(297.10), schizophreniform disorder (295.40), schizoaffective disorder(295.70), induced psychotic disorder (297.30), bipolar disorder, mixed(296.61, 296.62, 296.63, 296.64, 296.65, 296.66, 296.60), bipolardisorder, manic (296.41, 296.42, 296.43, 296.44, 296.45, 296.46,296.40), bipolar disorder, depressed (296.51, 296.52, 296.53, 296.54,296.55, 296.56, 296.50), major depression, single episode (296.21,296.22, 296.23, 296.24, 296.25, 296.26, 296.20), major depression,recurrent (296.31, 296.32, 296.33, 296.34, 296.35, 296.36, 296.30),obsessive compulsive disorder (300.30), post-traumatic stress disorder(309.89), generalized anxiety disorder (300.02), hypochondriasis(300.07), somatization disorder (300.81), male erectile disorder(302.72), intermittent explosive disorder (312.34), impulse controldisorder (312.39), paranoid (301.00), schizoid (301.20), schizotypal(301.22), antisocial (301.70), and borderline (301.83). Diagnostic andStatistical Manual of Mental Disorders, 3rd Ed. Revised, (1980),prepared by the Task Force on Nomenclature and Statistics of theAmerican Psychiatric Association.

The compounds of the present invention have been found to displayactivity in a 5-HT_(1c) receptor binding assay which measures theaffinity of the compounds to bind to 5-HT_(1c) receptors. The assayswere conducted by the following procedures.

I. Assay for 5-HT_(1C) Affinity

5-HT_(1c) selective compounds can be identified using the followingbiological assay procedures. Compounds having a selective affinity forthe 5-HT_(1c) receptor have a low IC₅₀ in the 5-HT_(1c) receptor assayand a higher IC₅₀ in the 5-HT₂ receptor assay. As shown by Table II(below) the compounds prepared in Examples 3, 4, 6, 7, 10, 13, 15, and16 are particularly 5-HT_(1c) selective.

IA. Biological Reagent Preparation

Beef brain was removed immediately after slaughter, and choroid plexuswere dissected over ice. Male Sprague-Dawley rats weighing 125-150 g(Harlan Industries, Cumberland, Ind.) were killed by decapitation. Thebrain of each was immediately removed and the cerebral cortex wasdissected over ice. Tissues were homogenized in 9 volumes of 0.32 mol/Lsucrose and centrifuged at 1,000×g for 10 minutes. The supernatant wascentrifuged at 17,000×g for 20 minutes. The pellet was suspended in 100volumes of 50 mM Tris-HCl (pH 7.4), incubated at 37° C. for 10 minutesand centrifuged at 50,000×g for 10 minutes, and the process was repeatedthree times. The final pellets were frozen at -70° C. and used within 2weeks. Pellets were rehydrated with physiological buffer prior to use.

II. Assay Procedure

Radioligand binding assays for 5-HT_(1c) and 5-HT₂ receptors wereconducted according to described methods. The assays can be conducted asdescribed by Hoyer D., Functional correlates of serotonin 5-HT₁recognition sites, J. Receptor Res 8, 59-81 (1988) and Hoyer D., EngelG., Kalkman H. O. Molecular pharmacology of 5-HT₁ and 5-HT₂ recognitionsites in rat and pig brain membranes: Radio-ligand binding studies with³ H!5-HT, ³ H!8-OH-DPAT, (-) ¹²⁵ I! iodocyanopindolol, ³ H!mesulergineand ³ H!ketanserin, Eur. J. Pharmacol. 118, 13-23 (1985).

For 5-HT_(1c) receptor assays increasing concentrations of experimentalcompound, 50 mM Tris HCl buffer pH 7.4, and tritiated mesulergine (2.0nM) (³ H ligand) were combined in polystyrene tubes at room temperature.The reaction was initiated by the addition of the resuspended choroidplexus tissue which had been preincubated at 37° C. for 20 minutes. Thereaction mixture was incubated in a 37° C. water bath for 15 minutes.

For 5-HT_(2B) receptor assays increasing concentrations of experimentalcompound, 50 mM Tris HCl buffer pH 7.4, and tritiated ketanserin (1 nM)(³ H ligand) were combined in polystyrene tubes at room temperature. Thereaction was initiated by the addition of the resuspended rat cerebralcortex tissue which had been preincubated at 37° C. for 20 minutes. Thereaction mixture was incubated in a 37° C. water bath for 30 minutes.

The reactions were terminated by rapid filtration, (Brandel CellHarvestor), through Whatman GF/B glass filters that had been presoakedin Tris buffer pH 7.4. The filters were then washed 2 times with 5 ml ofice cold Tris buffer pH 7.4. Washed filters were placed in scintillationvials and 10 ml RedySolv, (Brandel), was added and samples were countedin a Searle D-300 beta counter. Means and standard error statistics werecalculated for triplicate experimental determinations in certain cases.Mean values were obtained from three or more separate determinations.The incubation time for the reaction mixture was 15 minutes at 37° C.

Concentrations that caused a 50% inhibition of radioligand binding(IC₅₀) and Hill coefficient were obtained by computer-assistedregression analysis.

One particularly useful embodiment of this invention is that it providesselective ligands for the 5-HT_(2B) receptor. Compounds with a highaffinity for the 5-HT_(2B) receptor generally are cross-reactive withthe 5-HT_(2c) receptor as well. Now 5-HT_(2B) receptors can beselectively modulated using compounds of this invention at rates setforth above for blocking the effects of agonists at 5-HT_(2B) receptors.The selective affinity may provide treatments with fewer side effectsand will facilitate the development of additional therapeutic agents.

Certain compounds and intermediates of the present invention are usefulfor modulating 5-HT_(2B) receptors. The compounds which are most usefulfor binding a 5HT_(2B) receptor can be identified using the followingprocedures. Further, a useful in vivo model for demonstrating 5-HT_(2B)activity is provided infra.

II. Radioligand Binding Studies for 5-HT_(2B)

Membrane preparation from transformed cells. Suspension cells expressingthe cloned rat 5-HT_(2B) receptor were harvested by centrifugation at2,200×g for 15 min at 4° C. Kursar, J. D., D. L. Nelson, D. B.Wainscott, M. L. Cohen, and M. Baez, Mol. Pharmacol., 42: 549-557(1992). Membranes for the binding assays were prepared by vortexing thepellet in 50 mM Tris-HCl, pH 7.4 (0.5×10⁹ cells/30 ml). The tissuesuspension was then centrifuged at 39,800×g for 10 min at 4° C. Thisprocedure was repeated for a total of three washes, with a 10 minuteincubation at 37° C. between the first and second wash. The final pelletwas homogenized in 67 mM Tris-HCl, pH 7.4 (at 20-40 and 12.5 millioncells/ml, original cell number, for cells expressing low and relativelyhigh levels of the 5-HT_(2B) receptor, respectively) using a Tissumizer(Tekmar, Cincinnati, Ohio), setting 65 for 15 seconds.

³ H!5-HT binding studies. Binding assays were automated using a Biomek1000 (Beckman Instruments, Fullerton, Calif.) and were performed intriplicate in 0.8 ml total volume. Membrane suspension, 200 μl,(0.04-0.27 mg protein) and 200 μl of drug dilution in water were addedto 400 μl of 67 mM Tris-HCl, pH 7.4, containing 3H!5-HT, pargyline,CaCl₂, and L-ascorbic acid. Final concentrations of pargyline, CaCl₂ andL-ascorbic acid were 10 μM, 3 mM and 0.1%, respectively. Tubes wereincubated at 37° C. for 15 min or at 0° C. for 2 hours (bindingequilibria were verified for both of these conditions), then rapidlyfiltered using a Brandel cell harvester (Model MB-48R; Brandel,Gaithersburg, Md.) through Whatman GF/B filters which had been presoakedin 0.5% polyethylenimine and precooled with ice-cold 50 mM Tris-HCl, pH7.4. The filters were then washed rapidly four times with one mlice-cold 50 mM Tris-HCl, pH 7.4. The amount of ³ H!5-HT trapped on thefilters was determined by liquid scintillation spectrometry (ReadyProtein and Beckman LS 6000IC, Beckman Instruments, Fullerton, Calif.).For the saturation experiments, actual free radioligand concentrationswere determined by sampling the supernatant of parallel saturationexperiments in which bound radioactivity had been separated bycentrifugation. The concentration of ³ H!5-HT ranged from 0.02 to 5 nMand 0.6 to 63 nM for saturation experiments incubated at 0° C. and 37°C., respectively. 5-HT, 10 μM, or 1-naphthylpiperazine (1-NP), 10 μM,defined nonspecific binding. For competition experiments, six to twelveconcentrations of displacing drugs were used, spanning six log units,and the final concentration of ³ H!5-HT was 2 nM. Protein was determinedby the method of Bradford, using bovine serum albumin as the standard.Bradford, M. M., Anal. Biochem. 72: 248-254 (1976).

Statistical Analysis

The K_(d) and B_(max) values from the saturation assays were determinedfor best fit to a one-site or a two-site binding model using a partialF-test. De Lean, A., A. A. Hancock, and R. J. Lefkowitz, Mol. Pharmacol.21: 5-16 (1981). The following equation was used for a one-site bindingmodel, ##EQU1## where Bound=amount of ³ H!5-HT specifically bound,B_(max) =maximum number of binding sites, K_(d) =equilibriumdissociation constant and L!=free concentration of ³ H!5-HT, or atwo-site binding model, ##EQU2## where Bound=amount of ³ H!5-HTspecifically bound, B_(max1) =maximum number of high affinity bindingsites, B_(max2) =maximum number of low affinity binding sites, K_(d1)=equilibrium dissociation constant for the high affinity site, K_(d2)=equilibrium dissociation constant for the low affinity site and L!=freeconcentration of ³ H!5-HT. The IC₅₀ values from the competition assays,the binding parameters for the IP₃ standard curve and the EC₅₀ andE_(max) values from the IP₃ assays were determined by nonlinearregression analysis of four parameter logistic equations (Systat, SystatInc, Evanston, Ill.). De Lean, A., A. A. Hancock, and R. J. Lefkowitz,Mol. Pharmacol., 21: 5-16 (1981). The IC₅₀ values were converted toK_(i) values using the Cheng-Prusoff equation. Cheng, Y., and W. H.Prusoff, Biochem. Pharmacol., 22: 3099-3108 (1973).

                  TABLE I    ______________________________________    The following Cell assays use Human Cells    Compound  5HT.sub.2B Cells                          5HT.sub.2A Cells                                    5HT.sub.2C Cells    ______________________________________    Example 11              16.44       292.58    351.96    Example 15              22.07       86.48     195.44    Example 13              168.49      917.16    2172.86    Example 17              367.41      263.94    1108.87    Example 15              11.35       32.99     52.06    Example 8 9.56        123.93    220.51    Example 10              106.17      556.40    1117.00    Example 18              177.89      362.79    325.10    Isomer 18(1)              142.80      152.65    137.76    Isomer 18(2)              2894.33     1967.05   6211.80    Example 12              121.19      172.03    783.35    Example 9 52.54       53.65     202.60    Example 7 667.82      277.62    976.73    Example 6 839.63      3443.51   2641.21    Example 14              3520.31     1447.65   9247.06    ______________________________________

III. Assay Methods 5-HT_(2B) in vitro

Male Wistar rats (150-375 g; Laboratory Supply, Indianapolis, Ind.) weresacrificed by cervical dislocation, and longitudinal section of thestomach fundus were prepared for in vitro examination. Four preparationswere obtained from one rat fundus. Ring preparations of the extractedjugular vein were prepared as described by Hooker; Blood Vessels 14:1(1977) and Cohen, M. L. J. Pharamcol. Exp. Ther. 227:327 (1983). Tissueswere mounted in organ baths containing 10 mL of modified Krebs solutionof the following composition (millimolar concentrations): NaCl, 118.2,KCl, 4.6; CaCl₂.H₂ O, 1.6; KH₂ PO₄, 1.2; MgSO₄, 1.2; dextrose, 10.0; andNaHCO₃, 24.8. Tissue bath solutions were maintained at 37° C. andequilibrated with 95% O₂ and 5% CO₂. Tissues were placed under optimumresting force (4 g) and were allowed to equilibrate for approximately 1hour before exposure to the test compound. Isometric contractions wererecorded as changes in grams of force on a Beckman Dynograph withStatham UC-3 transducers.

Determination of Apparent Antagonist Dissociation Constant

Noncumulative contractile concentration-response curves for serotonin inthe fundus and cumulatative concentration response curves in the jugularvein were obtained by a stepwise increase in concentration after washingout the preceding concentrations every 15-20 minutes. Each agonistconcentration remained in contact with the tissue for approximately 2minutes and maximum response to each compound concentration wasmeasured. ED₅₀ values were taken as the concentration of agonist thatproduced half-maximal contraction. After control responses wereobtained, tissues were incubated with an appropriate concentration ofbuffer or antagonist for 1 hour. Responses to serotonin were thenrepeated in the presence of an antagonist. Concentration responsesutilized only one agonist and one antagonist concentration per tissue.In general, successive agonist responses in the presence of buffertreatment were unaltered (average dose ratio was 1.28±0.21).

Apparent antagonist dissociation constants (K_(B)) were determined foreach concentration of antagonist according to the following equation:

    K.sub.B = B!/(dose ratio-1)

where B! is the concentration of the antagonist and dose ratio is theED₅₀ of the agonist in the presence of the antagonist divided by thecontrol ED₅₀. Generally, parallel shifts in the concentration-responsecurves occurred in the presence of antagonists. The results wereexpressed as the negative logarithm of the K_(B) (i.e., -log K_(B)).Calculations were completed using known methods. Zaborowsky, B. R. J.Pharmacol. Methods 4:4165 (1980).

Compounds of this invention were tested and demonstrated 5-HT_(2B)receptor activity using this described in vitro method.

In vivo Studies

Sprague-Dawley Rats (250-300 g) were fasted overnight. The rats wereanesthetized with urethane (250 mg) delivered intraperitoneally. Theabdominal cavity was opened and strain guage transducers were sewn onthe antimesenteric border of the colon. The transducers were oriented torecord circular muscle contractions. The animal body temperature wasmaintained by a heating pad. An intravenous catheter was inserted intothe jugular vein for drug administration. The carotid blood pressure wasalso monitored. Output of the strain guage transducers was graphed on aBeckman Dynograph. Baseline motility was monitored for 30 minutes. Atthe end of the 30 minute period, a vehicle control dose was administeredand motility was recorded for an additional 15 minutes. A serotonin doseresponse was developed. Successively higher doses of serotonin wereadministered at 15 minute intervals. An ED₅₀ dose was calculated, whichwas the dose producing half maximal contraction. In antagonistexperiments, historical ED₅₀ dose was administered to validate theexperimental set up. Next, a dose of antagonist was given. The motilitywas monitored for 15 minutes. After the 15 minute monitoring, an ED₅₀dose was administered. Motility was evaluated by measuring the number ofcontractions and multiplying them by the amplitude of contractions overa set time period to provide a Motility Index. The percent inhibitionwas calculated from the vehicle (no antagonist) treated group. A minimumof three rats were used for each concentration and data from differentanimals was pooled to determine ED₅₀ values.

Compounds exhibiting activity at the 5HT_(2B) receptor are useful fortreating disorders related to the modulation of the 5HT_(2B) receptor.For example, compounds having 5HT_(2B) antagonist activity reduce thespasticity of the colon. Thus, these compounds are useful for thetreatment of functional bowel disorders including irritable bowelsyndrome and irritable bowel syndrome-related symptoms. Theantispasmodic effect of such compounds can reduce abdominal painassociated with functional bowel disorders. Additionally, the 5HT_(2B)receptor is localized in other organs such as the brain, bladder, bloodvessels, stomach, and uterus, indicating that additional conditions are5HT_(2B) mediated.

Compounds demonstrating activity at the 5HT_(2A) receptor can beutilized in the treatment or prevention of conditions related tomodulation of the 5HT_(2A) receptor. Examples of such conditions includehypertension, sleep disorders, hallucinogenic activity, psychosis,anxiety, depression, thermoregulation, feeding disorders, andhypotension. Leonard, B. E., International Clinical Psychopharmacology,7, 13-21 (1992).

While it is possible to administer a compound of the invention directlywithout any formulation, the compounds are preferably employed in theform of a pharmaceutical formulation comprising a pharmaceuticallyacceptable excipient and at least one compound of the invention. Suchcompositions contain from about 0.1 percent by weight to about 90.0percent by weight of a present compound. As such, the present inventionalso provides pharmaceutical formulations comprising a compound of theinvention and a pharmaceutically acceptable excipient therefor.

In making the compositions of the present invention, the activeingredient is usually mixed with an excipient which can be a carrier, ora diluent or be diluted by a carrier, or enclosed within a carrier whichcan be in the form of a capsule, sachet, paper or other container. Whenthe carrier serves as a diluent, it can be a solid, semi-solid, orliquid material which acts as a vehicle, excipient, or medium for theactive ingredient. Thus, the composition can be in the form of tablets,pills, powders, lozenges, sachets, cachets, elixirs, emulsions,solutions, syrups, suspensions, aerosols (as a solid or in a liquidmedium), and soft and hard gelatin capsules.

The compounds of the invention may be delivered transdermally, ifdesired. Transdermal permeation enhancers and delivery systems,including patches and the like, are well known to the skilled artisan.

Examples of suitable carriers, excipients, and diluents include lactose,dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calciumphosphate, alginates, calcium silicate, microcrystalline cellulose,polyvinylpyrrolidone, cellulose, tragacanth, gelatin, syrup, methylcellulose, methyl- and propylhydroxy- benzoates, talc, magnesiumstearate, water, and mineral oil. The formulations may also includewetting agents, emulsifying and suspending agents, preserving agents,sweetening agents or flavoring agents. The formulations of the inventionmay be formulated so as to provide quick, sustained, or delayed releaseof the active ingredient after administration to the patient byemploying procedures well known in the art.

The compounds of this invention may be delivered transdermally usingknown transdermal delivery systems and excipients. Most preferrably, acompound of this invention is admixed with permeation enhancersincluding, but not limited to, propylene glycol, polyethylene glycolmonolaurate, and azacycloalkan-2-ones, and incorporated into a patch orsimilar delivery system. Additional excipients including gelling agents,emulsifiers, and buffers may be added to the transdermal formulation asdesired.

For oral administration, a compound of this invention ideally can beadmixed with carriers and diluents and molded into tablets or enclosedin gelatin capsules.

The compositions are preferably formulated in a unit dosage form, eachdosage containing from about 1 to about 500 mg, more usually about 5 toabout 300 mg, of the active ingredient. The term "unit dosage form"refers to physically discrete units suitable as unitary dosages forhuman subjects and other mammals, each unit containing a predeterminedquantity of active material calculated to produce the desiredtherapeutic effect in association with a suitable pharmaceuticalcarrier.

In order to more fully illustrate the operation of this invention, thefollowing formulation examples are provided. The examples areillustrative only, and are not intended to limit the scope of theinvention. The formulations may employ as active compounds any of thecompounds of the present invention.

Formulation 1

Hard gelatin capsules are prepared using the following ingredients:

    ______________________________________                           Concentration                   Amount Per                           by Weight                   Capsule (percent)    ______________________________________    Trans-9-methyl-5-(1-                     250 mg     55.0    naphthylmethyl)-1,2,3,4-    4a,5,6,10c,octahydrocyclo-    penta a!pyrido 3,4-b!    indole, hydrochloride    starch dried     200 mg     43.0    magnesium stearate                      10 mg     2.0                     460 mg    100.0    ______________________________________

The above ingredients are mixed and filled into hard gelatin capsules in460 mg quantities.

Formulation 2

Capsules each containing 20 mg of medicament are made as follows:

    ______________________________________                             Concentration                    Amount Per                             by Weight                    Capsule  (percent)    ______________________________________    spiro-6,6 2-(3,5-dimethoxy)-                       20 mg      10.0    1,2,3,4-tetrahydronaphthyl!-    10-methyl-2,3,4,4a,5,6,7,11a-    octahydro-1H-indolo 2,3-c!-    quinuclidine, hydrochloride    starch             89 mg      44.5    microcrystalline   89 mg      44.5    cellulose    magnesium stearate                       2 mg       1.0                      200 mg     100.0    ______________________________________

The active ingredient, cellulose, starch, and magnesium stearate areblended, passed through a No. 45 mesh U.S. sieve and filled into a hardgelatin capsule.

Formulation 3

Capsules each containing 100 mg of medicament are made as follows:

    ______________________________________                             Concentration                    Amount Per                             by Weight                    Capsule  (percent)    ______________________________________    spiro-6,6 2-(3-fluoro-4-methoxy)-                      100 mg      30.00    1,2,3,4-tetrahydronaphthyl!-    10-methyl-2,3,4,4a,5,6,7,11a-    octahydro-1H-indolo 2,3-c!-    quinuclidine, hydrochloride    polyoxyethylene    50 mg      0.02    sorbitan    monooleate    starch powder     250 mg      69.98                      350 mg     100.00    ______________________________________

The above ingredients are thoroughly mixed and placed in an emptygelatin capsule.

Formulation 4

Tablets containing 10 mg of active ingredient are made as follows:

    ______________________________________                            Concentration                  Amount Per                            by weight                  Tablet    (percent)    ______________________________________    8-fluoro-10-phenoxy-                     10 mg       10.0    6-(1-naphthylmethyl)-    2,3,4,4a,5,6,7,11c-    octahydro-1H-indolo-     2,3-c!quinoline, tartrate    starch           45 mg       45.0    microcrystalline                     35 mg       35.0    cellulose    polyvinylpyrrolidone                     4 mg        4.0    (as 10% solution in    water)    sodium carboxymethyl                     4.5 mg      4.5    starch    magnesium stearate                     0.5 mg      0.5    talc             1 mg        1.0                    100 mg      100.0    ______________________________________

The active ingredient, starch and cellulose are passed through a No. 45mesh U.S. sieve and mixed thoroughly. The solution ofpolyvinylpyrrolidone is mixed with the resultant powders which are thenpassed through a No. 14 mesh U.S. sieve. The granule so produced isdried at 50°-60° C. and passed through a No. 18 mesh U.S. sieve. Thesodium carboxymethyl starch, magnesium stearate and talc, previouslypassed through a No. 60 mesh U.S. sieve, are then added to the granulewhich, after mixing, is compressed on a tablet machine to yield a tabletweighing 100 mg.

Formulation 5

A tablet formulation may be prepared using the ingredients below:

    ______________________________________                            Concentration                  Amount Per                            by Weight                  Tablet    (percent)    ______________________________________    8-methyl-10-methoxy-                    250 mg       38.0    6-(1-naphthylethyl)-    2,3,4,4a,5,6,7,11c-    octahydro-1H-indolo-     2,3-c!quinoline    microcrystalline                    400 mg       60.0    cellulose    silicon dioxide  10 mg       1.5    fumed    stearic acid     5 mg        0.5                    665 mg      100.0    ______________________________________

The components are blended and compressed to form tablets each weighing665 mg.

Formulation 6

Suspensions each containing 5 mg of medicament per 5 ml dose are asfollows:

    ______________________________________                         per 5 ml of                         suspension    ______________________________________    8-chloro-10-cyclopropyl-                           5       mg    6-(1-naphthylethyl)-    2,3,4,4a,5,6,7,11c-    octahydro-1H-indolo-     2,3-c!quinoline    sodium carboxymethyl cellulose                           50      mg    syrup                  1.25    ml    benzoic acid solution  0.10    ml    flavor                 q.v.    color                  q.v.    water                  q.s. to 5                                   ml    ______________________________________

The medicament is passed through a No. 45 mesh U.S. sieve and mixed withthe sodium carboxymethylcellulose and syrup to form a smooth paste. Thebenzoic acid solution, flavor and color is diluted with some of thewater and added to the paste with stirring. Sufficient water is thenadded to produce the required volume.

Formulation 7

An aerosol solution is prepared containing the following components:

    ______________________________________                     Concentration by                     Weight (percent)    ______________________________________    spiro-6,6 2-(3-ethyl-4-ethoxy)-                       0.25    1,2,3,4-tetrahydronaphthyl!-    10-methyl-2,3,4,4a,5,6,7,11a-    octahydro-1H-indolo 2,3-c!-    quinuclidine, maleate    ethanol            29.75    Propellant 22      70.00    (chlorodifluoromethane)                       100.00    ______________________________________

The active compound is mixed with ethanol and the mixture added to aportion of the Propellant 22, cooled to -30° C. and transferred to afilling device. The required amount is then fed to a stainless steelcontainer and diluted further with the remaining amount of propellant.The valve units are then fitted to the container.

Formulation 8

A tablet formulation may be prepared using the ingredients below:

    ______________________________________                              Concentration                     Amount Per                              by Weight                     Tablet   (percent)    ______________________________________    spiro-6,6 2-(3-ethyl-4-ethoxy)-                       250 mg      38.0    1,2,3,4-tetrahydro-6-methyl-naphthyl!-    10-methyl-2,3,4,4a,5,6,7,11a-    octahydro-1H-indolo 2,3-c!-    quinuclidine, maleate    microcrystalline   400 mg      60.0    cellulose    silicon dioxide     10 mg      1.5    fumed    stearic acid        5 mg       0.5                       665 mg     100.0    ______________________________________

The components are blended and compressed to form tablets each weighing665 mg.

We claim:
 1. A compound of formula I: ##STR13## wherein: Q is R₃₄ ; R₃₄is spirobicyclic or substituted spirobicyclic;R₁ and R₃, independently,are hydrogen or C₁ -C₃ alkyl; R₂ is hydrogen or C₁ -C₆ alkyl; A is##STR14## R₆ and R₇, independently, are hydrogen, C₁ -C₆ alkyl, C₂ -C₆alkenyl, halo, halo (C₁ -C₆) alkyl, halo(C₂ -C₆)alkenyl, COR₅, C₁ -C₁₀alkanoyl, CO₂ R_(5'), (C₁ -C₆ alkyl)_(m) amino, NO₂, --SR₅ or OR₅ ; orR₆ and R₇ together with the carbon atoms of group A form a 5- to8-member carbon ring; R₈ is an R₆ group, C₃ -C₈ cycloalkyl, substitutedC₃ -C₈ cycloalkyl, C₃ -C₈ cycloalkyl(C₁ -C₃)alkyl, phenyl, substitutedphenyl, C₅ -C₈ cycloalkenyl, substituted C₅ -C₈ cycloalkenyl, phenyl-(C₁-C₃)alkyl, C₅ -C₈ cycloalkenyl-(C₁ -C₃)alkyl, or C₇ -C₁₆ arylalkyl; m is1 or 2; R₅ is hydrogen or C₁ -C₄ alkyl; R_(5') is C₁ -C₄ alkyl; and R₃₀and R₃₁, independently, are C₁ -C₆ alkyl or C₂ -C₆ alkenyl; or apharmaceutically acceptable salt or solvate thereof.
 2. A pharmaceuticalformulation comprising a compound of claim 1 and one or morepharmaceutically acceptable excipients therefor.
 3. A method fortreating a mammal suffering from or susceptible to a conditionassociated with 5HT_(2B) modulation, which comprises administering tosaid mammal an effective amount of a compound of claim
 1. 4. A method ofclaim 3 for treating a mammal suffering from, or susceptible to aFunctional Bowel Disorder.
 5. A method of claim 3 for selectivelybinding 5-HT_(2B) receptors in mammals comprising administering to amammal requiring selective binding of a 5-HT_(2B) receptor, a receptorbinding dose wherein the compound selectively binds 5-HT_(2B) receptors.